Samsung Bioepis’ PYZCHIVA gains FDA approval as Stelara biosimilar
02 Jul 2024
Preview
Source: Pharmaceutical Technology
Samsung Bioepis has announced US Food and Drug Administration (FDA) approval for PYZCHIVA (ustekinumab-ttwe / SB17) as a biosimilar to Stelara (ustekinumab).
The approval includes subcutaneous injections of 45 mg/0.5 mL and 90 mg/mL, and an intravenous 130 mg/26 mL solution of the product.
PYZCHIVA is indicated for multiple conditions including moderate to severe plaque psoriasis, active psoriatic arthritis and moderately to severely active Crohn’s disease and ulcerative colitis.
The US regulator granted a provisional determination for PYZCHIVA’s interchangeability designation.
The approval is based on comprehensive evidence confirming its biosimilarity to Stelara.
See Also:Eisai and Bristol Myers Squibb terminate ADC development deal
Preview
Source: Pharmaceutical Technology
Orion to hand over exclusive rights to MSD for prostate cancer therapy
Preview
Source: Pharmaceutical Technology
This includes analytical, non-clinical and clinical data that show no significant differences in safety, purity and potency.
Further clinical evidence from a Phase III trial involving patients with moderate to severe plaque psoriasis supported the biosimilarity of SB17 to Stelara.
The study showed equivalent efficacy and comparable safety and pharmacokinetic profiles up to week 28.
The Phase III study also confirmed the biosimilarity of SB17 to Stelara in terms of efficacy, safety, pharmacokinetics and immunogenicity up to week 28.
Samsung Bioepis vice-president and regulatory affairs team leader Byoung In Jung stated: “The FDA approval of PYZCHIVA as a biosimilar to Stelara is an important milestone for patients living with inflammatory conditions, as biosimilars can offer more choice and access to biologic treatments.
“In addition, biosimilars have a potential to reduce the financial burden of healthcare systems, especially in the US where biologics account for more than 46% of the annual drug spending.”
Samsung Bioepis’s PYZCHIVA will be commercialised by SandozSandoz in the US.
In September 2023, the companies signed a commercialisation agreement for SB17 covering the US, Europe, Canada, Switzerland and the UK.
According to the settlement and licence agreement between Samsung Bioepis and Janssen Biotech, the licence period for PYZCHIVA in the US will commence on 22 February 2025.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.